Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Baral AJ"'
Autor:
Elf, S, Abdelfattah, NS, Baral, AJ, Beeson, D, Rivera, JF, Ko, A, Florescu, N, Birrane, G, Chen, E, Mullally, A
Mutations in calreticulin (CALR) are phenotypic drivers in the pathogenesis of myeloproliferative neoplasms. Mechanistic studies have demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive electrostatic charge o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::ef690aae93d6a1e5ddfb1835ab0c7e78
https://eprints.whiterose.ac.uk/125969/1/Blood.pdf
https://eprints.whiterose.ac.uk/125969/1/Blood.pdf
Autor:
de Boer EC; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands.; Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital Amsterdam University Medical Centre Amsterdam The Netherlands., Thielen AJ; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Langereis JD; Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences Radboudumc Nijmegen The Netherlands.; Radboud Center for Infectious Diseases, Radboudumc Nijmegen The Netherlands., Kamp A; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Brouwer MC; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Oskam N; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Jongsma ML; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Baral AJ; Translational and Clinical Research Institute Newcastle upon Tyne UK., Spaapen RM; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Zeerleder S; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands.; Department of Hematology, Luzerner Kantonsspital Luzern and University of Bern Bern Switzerland.; Department for BioMedical Research University of Bern Bern Switzerland., Vidarsson G; Department of Experimental Immunohematology, Sanquin Research, and Landsteiner Laboratory Amsterdam University Medical Center Amsterdam The Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands., Wouters D; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands.; Centre for Infectious Disease Control National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands., Pouw RB; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands.; Sanquin Health Solutions Amsterdam The Netherlands., Jongerius I; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centre Amsterdam The Netherlands.; Department of Pediatric Immunology, Rheumatology, and Infectious Diseases, Emma Children's Hospital Amsterdam University Medical Centre Amsterdam The Netherlands.
Publikováno v:
Clinical & translational immunology [Clin Transl Immunology] 2023 Jan 27; Vol. 12 (1), pp. e1436. Date of Electronic Publication: 2023 Jan 27 (Print Publication: 2023).
Autor:
Hallam TM; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Cox TE; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Smith-Jackson K; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Brocklebank V; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Baral AJ; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Tzoumas N; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Steel DH; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; Sunderland Eye Infirmary, Sunderland, United Kingdom.; Biosciences Institute, Newcastle University, International Centre for Life, Newcastle upon Tyne, United Kingdom., Wong EKS; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Shuttleworth VG; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Lotery AJ; Clinical and Experimental Sciences, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom., Harris CL; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Marchbank KJ; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom., Kavanagh D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.; National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.; National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre, Biomedical Research Building, Newcastle upon Tyne, United Kingdom.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 Dec 28; Vol. 13, pp. 1028760. Date of Electronic Publication: 2022 Dec 28 (Print Publication: 2022).
Autor:
Rivera JF; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and.; Division of Haematology and Immunology, Leeds Institute for Medical Research, St. James's University Hospital, University of Leeds, Leeds, United Kingdom., Baral AJ; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Nadat F; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Boyd G; York Biomedical Research Institute, University of York, York, United Kingdom., Smyth R; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Patel H; School of Life Sciences, University of Westminster, London, United Kingdom., Burman EL; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Alameer G; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Boxall SA; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Jackson BR; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and., Baxter EJ; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Laslo P; Division of Haematology and Immunology, Leeds Institute for Medical Research, St. James's University Hospital, University of Leeds, Leeds, United Kingdom., Green AR; Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Wellcome MRC Cambridge Stem Cell Institute and.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Kent DG; York Biomedical Research Institute, University of York, York, United Kingdom., Mullally A; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute, Cambridge, MA; and.; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Chen E; School of Molecular and Cellular Biology, Faculty of Biological Sciences, and.; School of Life Sciences, University of Westminster, London, United Kingdom.
Publikováno v:
Blood advances [Blood Adv] 2021 Apr 13; Vol. 5 (7), pp. 1922-1932.
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Autor:
Elf S; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Abdelfattah NS; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Baral AJ; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Beeson D; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Rivera JF; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Ko A; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Florescu N; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Birrane G; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA., Chen E; School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Mullally A; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Broad Institute, Cambridge, MA; and.; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Publikováno v:
Blood [Blood] 2018 Feb 15; Vol. 131 (7), pp. 782-786. Date of Electronic Publication: 2017 Dec 29.